期刊文献+

益生菌抗结肠癌作用及分子机制研究进展 被引量:5

Research Progress of Probiotics in Colon Cancer Prevention and Its Molecular Mechanism
原文传递
导出
摘要 益生菌是指一类通过改善肠内菌群平衡,对宿主起到有益作用的活性微生物,具有提高免疫力、抗过敏、缓解炎性肠道疾病、抗感染、抗癌等生物学功能。本文首先阐述益生菌、益生菌发酵液、其菌体成分、代谢成分抗结肠癌作用的研究进展;随后阐述其抗结肠癌的分子机制,主要包括;免疫调节和抗炎症作用,抑制细胞增殖和促进细胞凋亡,产生有益的代谢物和抑制致癌物活化酶与遗传解毒;最后介绍益生菌在临床医学研究中的应用情况,益生菌不仅可以在结肠癌发生过程中起到一定的保护作用,且能够很好的改善结肠术后患者的肠道相关症状。目前,益生菌菌体活性成分的分离及其功能研究也逐渐成为新的研究热点,这些将为更深入准确地了解益生菌的作用机制,更好的、更快的、更全面的利用益生菌及其制剂提供新的思路和途径。 Probiotics are usually live microorganisms which confer health benefits on host like improving intestinal flora balance.It can improve a number of physiological functions such as enhancing immunity,relieving hypersensitivity and inflammatory bowel disease,defencing infection,as well as anticancer,etc.This review summary the research progress of anti-colon-cancer effectiveness of probi-otics,its fermentation broth,its bacteria composition and metabolic compositions firstly.Then the molecular mechanisms of its anti-colon carcinoma properties are introduced.Its molecular mechanisms mainly includes: immune-modulatory properties and anti-inflammatory,inhibiting proliferation and promoting apoptosis,producing beneficial metabolites,inhibiting carcinogens-activated enzyme and an-ti-genotoxic activity.Finally,the applications of probiotics in clinic are presented.The results show that probiotics not only play a pro-tective role in the development of colon cancer,but also greatly improve the gut symptoms of patients with carcinoma after colostomy.At present,separation of active probiotic bacteria ingredients and its function research has become a research focus.These will provide the novel strategies and idea for exploring,exploiting and applying the products of probiotics in future.
出处 《现代生物医学进展》 CAS 2013年第4期769-771,共3页 Progress in Modern Biomedicine
基金 哈尔滨工业大学引进人才科研启动基金项目(AUGA9833213611)
关键词 益生菌 结肠癌 分子机制 Probiotics Colon cancer Molecular mechanism
  • 相关文献

参考文献3

二级参考文献12

  • 1朱云风 郭寿延.小鼠腹腔巨噬细胞表面C3b受体试验[J].上海免疫学杂志,1988,3(5):262-265.
  • 2赵予秀 彭虹 左秀勤.乳酸杆菌胞壁肽聚糖的佐剂作用及其抗感染效果.上海免疫学杂志,1988,8(1):1-4.
  • 3[1]Lidbeck CE,Nord JA,Gustafsson JR.Lactobacilli,anticarcinogenic activity and human intestinal microflira[J].Eur.J.Cancer Prev,1992,10:341-353.
  • 4[2]Pierre F,Perrin P,Champ M,et al.Short-Chain Fructo-Oligosaccharides Reduce the Occurrence of Colon Tumours and Develop Gut-Associated Lymphoid Tissue in Min Mice[J].Cancer Res,1997,57(2):225-228.
  • 5[3]Singh J,Rivernson A,Tomita M,et al.Bifidobacterium Longum,a Lactic acid producing intestinaL bacterium inhibits coLon cancer and moduLates the intermediate biomarkers of colon[J].Carcinogenesis,1997,18(4):833-841.
  • 6[4]AngeLo PF,Cristina L,Piero D,et al.Antitumorenic activity of the prebiotic inuLin enriched with oLofructose in combination with the probiotics LactobaciLLus rhamnosus and Bifidobacterium Lactis on azoxymethane-induced coLon carcinogenesis in rats[J].Carcinogenesis,2002,23(11):1953-1960.
  • 7[5]BoLognani F,Rumney CJ,PooL-ZobeL BL,et al.Effect of LactobaciLLi,bifidobacteria and inuLin on the formation of aberrant crypt foci in rats[J].Eur J Nutr,2001,40(6):293-300.
  • 8[6]Classen E,Van Vinsen R,Posko M,et al.New and safe "oral" live vaccines based on Lactobacillus[J].Adv Exp Med Biol,1995,371B:1553-1558.
  • 9[7]WoLLowski I,Rechkemmer G,PooL-ZobeL BL.Protective roLe of probiotics and prebiotics in coLon cancer[J].Am J CLin Nutr,2001,73(2):451-455.
  • 10[8]Linda J,Brady D,Gallaher F.The roLe of probiotic cuLtures in the prevention of coLon cancer[J].J Nutr,2000,130:410-414.

共引文献40

同被引文献53

  • 1Demers M, Dagnault A, Desjardins J. A randomized double-blind controlled trial: Impact of probiotics on diarrhea in patients treated with pelvic radiation[J]. Clin Nutr, 2013, 24(13): 274-279.
  • 2Sharma M, Devi M. Probiotics: A Comprehensive Approach toward Health Foods[J]. Crit Rev Food Sci Nutr, 2014, 54(4): 537-552.
  • 3De Moreno, De Leblanc A, Perdigo n G. The application ofprobiotic fermented milks in cancer and intestinal inflammation [J]. Proceedings of the Nutrition Society, 2010, 69(3): 421-428.
  • 4Anabrees J,Indrio F, Paes B, et al. Probiotics for infantile colic: a systematic review[J]. BMC Pediatr, 2013, 13(1 ): 186-191.
  • 5Versalovie J. The human microbiome and probioties: implications for pediatrics[J]. Ann Nutr Metab, 2013, 63(2): 42-52.
  • 6Coyle VM, Lungulescu D, Toganel C, et al. A randomised double-bli- nd placebo-controlled phase II study of AG1004 for control of chemotherapy-induced diarrhoea [J]. Br J Cancer, 2013, 108 (5): 1027-1033.
  • 7Mizushima T, Ide Y, Murata K, et al. A Phase II Study of Combined Chemotherapy with 5-Week Cycles of S-1 and CPT-11 plus Bevacizumab in Patients with Metastatic Colon Cancer[J]. Ontology, 2013, 85(6): 317-322.
  • 8Merkow RP, Bentrem DJ, Mulcahy MF, et al. Effect of Postoperative Complications on Adjuvant Chemotherapy Use for Stage III Colon Cancer[J]. Ann Surg, 2013, 258(6): 847.
  • 9文艳花.新生儿高胆红素血症的临床研究进展[J].中国药物经济学,2013,(2):360.
  • 10Regalo G1,Resende C,Wen X,et al. C/EBP alpha expression is asso-ciated with homeostasis of the gastric epithelium and with gastric carci-nogenesis [J]. Lab Invest,2010,90(8) :1132-1139.

引证文献5

二级引证文献38

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部